...
首页> 外文期刊>Cell death & disease. >Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells
【24h】

Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells

机译:3-羟基-3-甲基戊二酰辅酶A还原酶的诱导介导乳腺癌细胞中他汀类药物耐药

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The mevalonate pathway has emerged as a promising target for several solid tumors. Statins are inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of this pathway, and are commonly used to treat patients with hypercholesterolemia. Pleiotropic antitumor mechanisms of statins have been demonstrated for several human cancer types. However, cancer cells differ in their individual statin sensitivity and some cell lines have shown relative resistance. In this study we demonstrate, that the human breast cancer cell lines MDA-MB-231, MDA-MB-468, MCF-7, and T47D are differentially affected by statins. Whereas the vitality of MDA-MB-231 and MDA-MB-468 cells was reduced by up to 60% using atorvastatin, simvastatin, or rosuvastatin (p??0.001), only marginal effects were seen in T47D and MCF-7 cells following exposure to statins. Statin treatment led to an upregulation of HMGCR mRNA and protein expression by up to sixfolds in the statin-resistant cells lines (p??0.001), but no alterations of HMGCR were observed in the statin-sensitive MDA-MB-231 and MDA-MB-468 cells. The knockdown of HMGCR prior to statin treatment sensitized the resistant cell lines, reflected by a 70% reduction in vitality, increased apoptotic DNA fragmentation (sixfold) and by accumulation of the apoptosis marker cleaved poly-ADP ribose polymerase. Statins induced a cleavage of the sterol-regulatory element-binding protein (SREBP)-2, a transcriptional activator of the HMGCR, in T47D and MCF-7 cells. The inhibition of SREBP-2 activation by co-administration of dipyridamole sensitized MCF-7 and T47D cells for statins (loss of vitality by 80%; p??0.001). Furthermore, assessment of a statin-resistant MDA-MB-231 clone, generated by long-term sublethal statin exposure, revealed a significant induction of HMGCR expression by up to 12-folds (p??0.001). Knockdown of HMGCR restored statin sensitivity back to levels of the parental cells. In conclusion, these results indicate a resistance of cancer cells against statins, which is in part due to the induction of HMGCR.
机译:甲羟戊酸途径已经成为一些实体瘤的有希望的靶标。他汀类药物是该途径的限速酶3-羟基-3-甲基戊二酰辅酶A还原酶(HMGCR)的抑制剂,通常用于治疗高胆固醇血症患者。他汀类药物的多效抗肿瘤机制已针对几种人类癌症类型进行了证实。但是,癌细胞对他汀类药物的敏感性不同,并且某些细胞系显示出相对抗性。在这项研究中,我们证明了他汀类药物对人乳腺癌细胞MDA-MB-231,MDA-MB-468,MCF-7和T47D有不同的影响。使用阿托伐他汀,辛伐他汀或瑞舒伐他汀可使MDA-MB-231和MDA-MB-468细胞的活力降低多达60%(p 0.001),而在T47D和MCF-7细胞中仅观察到边缘作用接触他汀类药物后。他汀类药物治疗导致他汀类药物耐药细胞系中HMGCR mRNA和蛋白表达上调多达6倍(p 0.001),但在他汀类药物敏感性MDA-MB-231和MDA中未观察到HMGCR改变-MB-468细胞。他汀类药物治疗前HMGCR的敲低使耐药细胞株敏感,反映为活力降低70%,凋亡DNA片段增加(六倍)和凋亡标记物裂解的聚ADP核糖聚合酶的积累。他汀类药物诱导了T47D和MCF-7细胞中HMGCR转录激活因子固醇调节元件结合蛋白(SREBP)-2的裂解。通过联用双嘧达莫致敏的MCF-7和T47D细胞对他汀类药物抑制SREBP-2活化(活力损失80%; p <0.001)。此外,对长期致死性他汀类药物暴露产生的对他汀类药物耐药的MDA-MB-231克隆的评估显示,HMGCR表达可被诱导高达12倍(p <0.001)。击倒HMGCR使他汀类药物敏感性恢复到亲代细胞水平。总之,这些结果表明癌细胞对他汀类药物具有抗性,这部分归因于HMGCR的诱导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号